Abstract
Background and objective
During the drug development process, phase I trials are the first occasion to study the pharmacokinetics of a drug. They are performed in healthy subjects, or in patients in oncology, and are designed to determine a safe and acceptable dose for the later phases of clinical trials. We performed a bibliographic survey to investigate the way pharmacokinetics are described and reported in phase I clinical trials.
Methods
We performed a MEDLINE search to retrieve the list of papers published between 2005 and 2006 and reporting phase I clinical trials with a pharmacokinetic study. We used a spreadsheet to record general information concerning the study and specific information regarding the pharmacokinetics, such as the sampling times, number of subjects and method of analysis.
Results
The search yielded 349 papers, of which 37 were excluded for various reasons. Nearly all of the papers in our review concerned cancer studies, although this was not a requirement in the search. Consistent with the selection process, 84% papers explicitly stated pharmacokinetics as an objective of the study. The methods section usually included a description of the pharmacokinetics (88%), but 10% of the papers provided no information concerning the methods used for the pharmacokinetics and in 2% the description was only partial. The analytical method was usually basic, with non-compartmental or purely descriptive methods. Observed concentrations and areas under the concentration-time curves were the pharmacokinetic variables most often reported. The results of the pharmacokinetic study were frequently reported in a separate paragraph of the results section, and only 22% of the studies related the pharmacokinetic findings to other results from the study, such as toxicity or efficacy. In addition, important information such as the number of subjects included in the pharmacokinetic study or the pharmacokinetic sampling scheme was sometimes not reported explicitly.
Conclusion
Concerns about the decreasing cost-effectiveness of the drug development process prompted the regulatory authorities to recently recommend better integration of all available information — including, in particular, pharmacokinetics — in this process. In our review, we found that this information was often either missing or incomplete, which hinders that objective. We suggest several improvements in the design and the reporting of the methods and results of these studies, to ensure that all relevant information has been included. Pharmacokinetic findings should also be integrated into the broader perspective of drug development, through the study of their relationship with toxicity and/or efficacy, even in the early phase I stages.
Similar content being viewed by others
References
Reigner B, Blesch K. Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol 2002; 57(12): 835–45
Zhou Y. Choice of designs and doses for early phase trials. Fundam Clin Pharmacol 2004; 18(3): 373–8
Aarons L, Karlsson MO, Mentré F, et al. Role of modelling and simulation in phase I drug development. Eur J Pharm Sci 2001; 13: 115–22
US FDA. Guideline for the format and content of the human pharmacokinetics and bioavailability section of an application. Rockville (MD): FDA, 1987 Feb [online]. Available from URL: http://www.fda.gov/CDER/GUIDANCE/old071fn.pdf [Accessed 2009 May 21]
Dingemanse J, Appel-Dingemanse S. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet 2007; 46: 713–37
Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000; 25: 49–58
US FDA. Innovation or stagnation: critical path opportunities report. Rockville (MD): FDA, 2006 Mar [online]. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf [Accessed 2009 May 21]
Chien J, Friedrich S, Heathman M, et al. Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 2005; 7: E544–59
Pillai G, Mentré F, Steimer JL. Non-linear mixed effects modeling: from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005; 32: 161–83
Retout S, Mentré F. Optimization of individual and population designs using SPlus. J Pharmacokinet Pharmacodyn 2003; 30: 417–43
Boutron I, Tubach F, Giraudeau B, et al. Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis. JAMA 2003; 290: 1062–70
R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2004 [online]. Available from URL: http://www.R-project.org [Accessed 2009 May 21]
US FDA. Guidance for industry: population pharmacokinetics. Rockville (MD): FDA, 1999 Feb [online]. Available from URL: http://www.fda.gov/cder/guidance/1852fnl.pdf [Accessed 2009 May 21]
Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005; 7: E503–9
Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163–9
Margolin K, Synold T, Longmate J, et al. Methodologic guidelines for the design of high-dose chemotherapy regimens. Biol Blood Marrow Transplant 2001; 7: 414–32
Strevel EL, Chau NG, Pond GR, et al. Improving the quality of abstract reporting for phase I cancer trials. Clin Cancer Res 2008; 14: 1782–7
Acknowledgements
The authors wish to thank Dr Isabelle Boutron for helpful discussions and advice, and Dr Karl Brendel for reading the manuscript.
No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Comets, E., Zohar, S. A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology. Clin Pharmacokinet 48, 387–395 (2009). https://doi.org/10.2165/00003088-200948060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200948060-00004